New weapon against advanced cancer enters human testing
NCT ID NCT05378425
Summary
This is the first study in people to test a new drug called NTX-1088, an antibody designed to target a protein found on many cancer cells. The main goals are to find safe doses and see how the body processes the drug, both by itself and when combined with an existing immunotherapy (pembrolizumab). It is for adults with advanced solid tumors that have stopped responding to standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
Contact
-
Hadassah Medical Center
RECRUITINGJerusalem, 9574425, Israel
Contact
-
Maria Skłodowska-Curie National Research Institute of Oncology
NOT_YET_RECRUITINGWarsaw, Poland
Contact
-
Ochsner Clinic Foundation
RECRUITINGNew Orleans, Louisiana, 70121, United States
Contact
-
Sheba Medical Center
RECRUITINGRamat Gan, 5262131, Israel
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.